PTSM: Pharmaceutical Technology Sourcing and Management-12-06-2017

Formulation and excipient advances address taste masking concerns to improve medication adherence in pediatric, geriatric, and other special patient populations.

As regulatory authorities crack down on data integrity violations, bio/pharma companies must ensure adequate data governance programs are in place.

Understanding the relative strengths and weaknesses of different endotoxin test methods is crucial to maintaining quality and patient safety.

Lonza has entered into strategic license agreements for exclusive rights to a gene-therapy platform for developing treatments for hearing and balance disorders.

Manufacturers and trading partners struggle to meet drug tracking requirements

The facilities in Brescia, Italy and Karlskoga and Uppsala, Sweden, are the latest of Recipharm’s sites to be equipped to supply serialized products to the United States.

Understanding what affects a measurement and implementing appropriate procedures will aid weighing accuracy.

Avista Pharma Solutions facility and equipment upgrades at its Longmont, Colorado facility support processing of potent compounds.

MasterControl has added three new cloud-based analytical solutions to its MasterControl Version 11.7 software for clinical managers and regulatory/submissions professionals.

The company has completed a small-scale capacity expansion at its site in Charles City, IA.

Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.

Alcami will manufacture clinical supply of the API for a drug candidate targeting various hematologics and solid cancers.

QuintilesIMS has changed its name to IQVIA to reflect its October 2016 merger with IMS Health.

The company has officially opened a local brand office in South Korean to support its existing business in the region.

The debate continues over biosimilar naming, interchangeability, and patent protection, as well as lingering concerns in the medical community about the safety of switching patients to new therapies.

Acquisition activity has created some CDMOs with facilities and capabilities that rivals global bio/pharma companies.